title: Carotid Baroreceptor Stimulation and Arteriovenous Shunts for Resistant Hypertension.
abstract: Pharmacologic therapy for hypertension is effective for the majority of patients with hypertension, but there is a subset of the population with treatment-resistant hypertension who cannot achieve their blood pressure goal despite taking multiple medications. Since these patients are at increased risk of cardiovascular disease and end-organ damage, additional therapies must be considered. This review discusses several novel interventional therapies-including baroreflex activation therapy, baroreceptor stenting, and creation of an arteriovenous shunt-that may provide alternative options for blood pressure control in those with treatment-resistant hypertension. All of these therapies remain investigational, and each has its own strengths and weaknesses that will be critical to assess as they come to market.
authors.affiliation: University of Rochester Medical Center, Rochester, New York.
authors.forename: Nicholas
authors.initials: N
authors.lastname: Paivanas
authors.affiliation: University of Rochester Medical Center, Rochester, New York.
authors.forename: John D
authors.initials: JD
authors.lastname: Bisognano
authors.affiliation: University of Rochester Medical Center, Rochester, New York.
authors.forename: John P
authors.initials: JP
authors.lastname: Gassler
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001166:Arteriovenous Shunt, Surgical; D017704:Baroreflex; D001794:Blood Pressure / Q000187:drug effects; D004351:Drug Resistance; D004599:Electric Stimulation Therapy / Q000295:instrumentation / Q000379:methods*; D057510:Endovascular Procedures / Q000295:instrumentation; D006801:Humans; D006973:Hypertension / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D058117:Neural Prostheses; D011311:Pressoreceptors / Q000503:physiopathology*; D011474:Prosthesis Design; D015607:Stents; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents
keywords: Rheos Pivotal Trial; arteriovenous shunt; baroreflex activation therapy; carotid nitinol stent; treatment-resistant hypertension